ReviewInflammopharmacology2025
URAT1 and GLUT9 as drug targets in gout: progress in transporter-directed therapies and delivery technologies.
Review in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Hirudin Attenuates Uric Acid-Induced Renal Tubular Injury via TNFRSF6B-Mediated Suppression of NF-κB Signaling.Pharmacology research & perspectives · 2026Article
- Article
- From uric acid to tophi: multistage molecular and cellular mechanisms of tophi formation.Frontiers in immunology · 2026Review
- IndobufenPeerJ · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gout is a disorder of metabolism characterized by the deposition of urine crystals, and hyperuricemia, the treatment of which was uricosuric agent and xanthine oxidase inhibitor. Recently, attention has been paid to inhibitors of urate transporters, especially URAT1 and GLUT9, for the possibility of increasing uric acid excretion and decreasing serum uric acid levels in the last few years. The article discusses the physiological functions of URAT1 and GLUT9, genetic associations of these proteins with gout, and novel applications of drug delivery aimed at these proteins. This review comprises of clinical reports, and pharmacology updates regarding urate transporters and transport inhibitors. The role of genetic variants on the functioning of transporters were established and novel drug formulations were examined. The article discusses innovations in drug-delivery systems including sustained-release devices, liposomes, and nanoparticles to circumvent pharmacokinetic limitations and improve therapeutic efficacy. The advent of gene therapy and CRISPR editing for the modification of transporters could also be promising for the treatment of hyperuricemia. The integration of transporter-targeted therapy and new drug delivery systems may dramatically change the landscape of gout treatment in terms of safety and personalized treatment options.
Indexed as
Identifiers
41065961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.